Hepatol Commun. 2020 Mar 13;4(5):631-645. doi: 10.1002/hep4.1503. eCollection 2020 May.
Hepatology communications
Naemat Sandhu, Victor Navarro
PMID: 32363315 PMCID: PMC7193133 DOI: 10.1002/hep4.1503
Although drug-induced liver injury (DILI) is a rare clinical event, it carries significant morbidity and mortality, leaving it as the leading cause of acute liver failure in the United States. It is one of the most challenging diagnoses encountered by gastroenterologists. The development of various drug injury networks has played a vital role in expanding our knowledge regarding drug-related and herbal and dietary supplement-related liver injury. In this review, we discuss what defines liver injury, epidemiology of DILI, its biochemical and pathologic patterns, and management.
© 2020 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.